Group items tagged

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

A progress analysis on current and emerging drugs on the peptide drug development the reveals promising investment opportunities. Popular products included in the package are Cancer Peptides: From First-in-Class to Best-in-Class; and Peptides in Oncology Drug Pipeline Update 2013.

Real estate was the largest asset class for HNWIs in the UAE in 2012, accounting for 23.2% of total HNWI assets. Cash products recorded the strongest growth during 2008 to 2012, driven by a movement to safer assets during the financial crisis. Cash is expected to be the worst performing asset class resulting in a movement away from cash and towards equities.

Novel approaches to treat infection is growing as the need is urgent. Misuse or overuse of antibiotics accelerated Anti-Microbial Resistance (AMR) and has resulted in the emergence of super bugs which are posing life threatening challenges worldwide. Novel approaches are immediately required to combat these super infections warranting need for new classes of antibiotics and other preventive/therapeutic approaches.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs, Dengue - Pipeline Review, H1 2014, provides an overview of the Dengues therapeutic pipeline. It also enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Food service includes the sale of food and drinks prepared outside of the home for immediate consumption either on the premises where they are bought or in the case of takeaways and home delivery transactions, at home. It also includes meals that are prepared outside of the home and catered to students, or the working and business classes.